Aerial view of the Central park in New York with golf fields and tall skyscrapers surrounding the park.

Comparative Efficacy Studies Are No Longer the Default Requirement for Biosimilars

Start
Our FDA: Drug & Device Team examines the FDA’s new draft guidance that allows biosimilar developers to rely more on analytical and pharmacokinetic data, reducing the need for costly and time-consuming comparative efficacy studies….
By: Alston & Bird
Previous Story

The AI Advantage in Discovery: How AI is Already Driving Efficiency and Defensibility

Next Story

Blockchain & Cryptocurrency Regulation 2026: Canada